Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging
A wave of biotechs is making the milestone move from drug developer to drug marketer, but investors are less interested than ever in sticking around for the potential long-term rewards.
You may also be interested in...
Jakafi Launch Going Smoothly, But Incyte Confuses Investors
Incyte reported its second quarter results Aug. 2, but failed to communicate its intentions clearly regarding a shift in accounting.
Incyte’s Jakafi Gets Additional Claim Based On Patient-Reported Outcomes
Jakafi is the first approved treatment for myelofibrosis, a rare bone marrow cancer, but Incyte will also be able to claim efficacy against the symptoms of the disease thanks to data in labeling from a patient-reported outcomes tool.